The Global Recombinant Chemicals Market is valued at approximately USD 2.9 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 7.8% over the forecast period 2024-2032.

Q4 2024 Earnings Call Transcript March 26, 2025 Dyadic International, Inc. misses on earnings expectations. Reported EPS is $ ...

Strongrevenueperformance,includingapproximately$1.9millionmilestoneandlicenserevenuerecognizedin2024Up to $7.5 million in grants awarded from ...

Custom Recombinant Protein Production Services Market 2025 custom recombinant protein production services market is estimated to be valued ...

Furthermore, Dyadic is advancing the development of recombinant fibro breast growth factor -- FGF products for cell culture media and biopharmaceutical applications. As a critical driver of cell ...

ABEC, a global leader in engineered solutions and services for biotech manufacturing, has introduced its Advanced Therapy ...

EMA committee recommends approval of Bristol Myers Squibb’s subcutaneous formulation of Opdivo across multiple solid tumour indications: Princeton, New Jersey Monday, March 31, ...

Bristol Myers (BMY) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended approval ...

AIM Vaccine Co., Ltd. (06660.HK), a leading PRC vaccine company, published its 2024 Annual Results announcement on March 30, 2025, the company recorded revenues of RMB 1,285 million in 2024, an ...

Korea Investment CORP grew its position in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) by 362.5% ...